Translating PIK3CA Biology in Vascular Malformations: A Pharma-Dx Collaboration to Accelerate Patient Impact
- Overview of vascular malformations (VMs), clinical burden, and the heterogeneity that drives the need for molecularly guided approaches
- Role of PIK3CA mutations in VM subsets and OnKure Therapeutics’ development of a pan-mutant selective
- PI3KA inhibitor to translate pathway insight into targeted treatment options
- Partnership with Foundation Medicine to deliver genomic testing for PIK3CA and other disease-related alterations supporting patient identification, exploring genotype-phenotype relationships, and research advancement